These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31883408)

  • 1. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
    Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
    Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
    Li H; Xi Y; Liu H; Xin X
    Front Nutr; 2022; 9():914079. PubMed ID: 36091227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro.
    Zheng Y; Zhao J; Miao D; Xu T; Wang L; Liu C; Gao Y; Yu L; Shen C
    Biomed Pharmacother; 2023 Aug; 164():114957. PubMed ID: 37295248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.
    Lin C; Yu B; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Front Pharmacol; 2022; 13():880508. PubMed ID: 35614939
    [No Abstract]   [Full Text] [Related]  

  • 12. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
    Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
    Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 19. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor.
    Xu W; Cui C; Cui C; Chen Z; Zhang H; Cui Q; Xu G; Fan J; Han Y; Tang L; Targher G; Byrne CD; Zheng MH; Yang L; Cai J; Geng B
    Hepatology; 2022 Dec; 76(6):1794-1810. PubMed ID: 35586979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.